Pharmacogenomic-Guided Medication Management for Depression

(COMPASS-PGx Trial)

This trial explores whether genetic information can help pharmacists manage antidepressant medications more effectively. It focuses on individuals who have recently started or changed their antidepressant prescription and have mild depressive symptoms. Participants will either receive personalized medication management based on their genetic test results (comprehensive medication management with pharmacogenomic results) or follow the usual care routine. The goal is to determine if this personalized approach leads to better outcomes in managing depression. This trial may suit English-speaking individuals who are patients at specific pharmacies and have agreed to participate in a biobanking research study. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance personalized medicine for depression.

The trial does not specify if you need to stop your current medications. It focuses on managing antidepressant treatment, so you might need to adjust your antidepressant medication, but it's best to discuss this with the trial team.

Research has shown that pharmacogenomic (PGx) testing, which examines how genes affect a person's reaction to medications, can safely guide depression treatment. One study found that patients using medications chosen with PGx testing were 41% to 78% more likely to experience symptom relief and 20% to 49% more likely to respond well to treatment. This suggests that using PGx testing to select medications can be both effective and safe.

Another study indicated that PGx-guided treatment can improve symptom relief and response rates in depression without major safety concerns. The treatment was generally well-tolerated, with no significant side effects reported.

Researchers are excited about using pharmacogenomic-guided medication management for depression because it personalizes treatment by using a patient's genetic information to tailor medication choices. Unlike the standard trial-and-error approach with antidepressants like SSRIs or SNRIs, this method aims to improve effectiveness and reduce side effects by identifying the best-suited medications from the start. This innovative approach could lead to faster relief from symptoms and a more efficient path to finding the right treatment for each individual.

Research shows that using gene testing to guide antidepressant treatment can improve outcomes for people with depression. In this trial, participants in the experimental arm will receive comprehensive medication management with pharmacogenomic (PGx) testing results. Some studies have found that patients who underwent this testing experienced improvements in managing their depression. Specifically, gene testing can increase the chances of remission, meaning symptoms of depression can greatly decrease or disappear. Several studies have demonstrated that gene testing enhances treatment effectiveness, yielding clear positive results. This testing proves especially useful for treating major depressive disorder, where finding the right medication can be challenging.³⁶⁷⁸⁹